{"gene":"GORAB","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2008,"finding":"GORAB (SCYL1BP1) localizes to the Golgi apparatus and interacts with the small GTPase RAB6, identifying it as a golgin. Loss-of-function mutations in SCYL1BP1 cause gerodermia osteodysplastica, a disorder affecting skin and bone, establishing the Golgi/secretory pathway as the disease mechanism.","method":"Mutation identification in patients, subcellular localization experiments, protein-protein interaction assays","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — Golgi localization and RAB6 interaction established by direct experiments in a landmark disease-gene paper, replicated by subsequent studies","pmids":["18997784"],"is_preprint":false},{"year":2015,"finding":"GORAB localizes preferentially to trans-Golgi markers and is rapidly displaced upon Brefeldin A treatment, indicating a loose membrane association. An internal Golgi-targeting RAB6 and ARF5 binding (IGRAB) domain mediates binding to both RAB6 and ARF5 (in its active GTP-bound form). Two pathogenic missense mutations (p.Ala220Pro and p.Ser175Phe) fall within the IGRAB domain: p.Ala220Pro causes cytoplasmic mislocalization and abolishes both RAB6 and ARF5 binding, while p.Ser175Phe displaces GORAB to vesicular structures and selectively impairs ARF5 binding.","method":"Yeast two-hybrid screening, subcellular localization by fluorescence microscopy, Brefeldin A treatment, site-directed mutagenesis of disease-associated missense mutations","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Y2H, microscopy, mutagenesis, BFA displacement), reciprocal binding assays, mechanistic mapping of disease mutations to a defined domain","pmids":["26000619"],"is_preprint":false},{"year":2019,"finding":"GORAB acts as a COPI scaffolding factor at the trans-Golgi. It forms stable domains at the trans-Golgi that, via interactions with the COPI-binding protein SCYL1, promote COPI recruitment to these domains. Loss of GORAB impairs COPI-mediated retrieval of trans-Golgi enzymes, resulting in deficient glycosylation of secretory cargo proteins. Pathogenic GORAB mutations perturb either SCYL1 binding or GORAB assembly into domains.","method":"Co-immunoprecipitation, GORAB knockout/knockdown, COPI recruitment assays, glycosylation assays of secretory cargo, analysis of pathogenic missense mutations","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods in a single rigorous study (Co-IP, KO functional assays, glycosylation readout, mutant analysis), mechanistically places GORAB in the COPI pathway","pmids":["30631079"],"is_preprint":false},{"year":2012,"finding":"SCYL1BP1 (GORAB) inhibits nerve growth factor-mediated neurite outgrowth in PC12 cells and impairs morphogenesis of primary cortical neurons by reducing p53 protein levels in a manner dependent on its transcriptional activator domain. SCYL1BP1 directly induces Mdm2 transcription, leading to Mdm2-mediated degradation of p53; siRNA knockdown of Mdm2 partially rescues the neurite outgrowth defects. In vivo, SCYL1BP1 suppresses axonal regeneration, while shRNA-mediated knockdown enhances it.","method":"Overexpression and shRNA knockdown in PC12 cells and primary neurons, neurite outgrowth assay, p53 protein measurement, Mdm2 promoter transcription assay, siRNA epistasis, in vivo axonal regeneration model","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cellular assays and in vivo experiments in a single lab, with epistasis through Mdm2 siRNA rescue","pmids":["23051735"],"is_preprint":false},{"year":2010,"finding":"Overexpression of SCYL1BP1 (GORAB) stabilizes p53 protein by suppressing MDM2-mediated ubiquitination of p53. This effect is specific to MDM2, as SCYL1BP1 does not alter p53 ubiquitination by HPV E6. Elevated SCYL1BP1 leads to increased p21 and GADD45 transcription, reduced proliferation, increased apoptosis, and inhibition of tumorigenicity.","method":"Ubiquitination assay, p53 protein level measurement, transcriptional reporter assays, cell proliferation and apoptosis assays, tumorigenicity assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ubiquitination assay with MDM2 specificity control (HPV E6 negative result), multiple functional readouts, single lab","pmids":["20849854"],"is_preprint":false},{"year":2009,"finding":"Mutations in SCYL1BP1 (GORAB) identified in Saudi families with gerodermia osteodysplastica include a missense mutation that produces a phenotype indistinguishable from null mutations, supporting that loss of GORAB golgin function is the pathogenic mechanism.","method":"Homozygosity mapping, linkage analysis, mutation identification","journal":"American journal of medical genetics. Part A","confidence":"Low","confidence_rationale":"Tier 3 / Weak — genetic mapping and mutation identification without direct mechanistic assay; supports but does not extend the functional model","pmids":["19681135"],"is_preprint":false},{"year":2017,"finding":"Conditional deletion of Gorab in long bones (GorabPrx1 mice) results in decreased cortical bone area, thickness, and moments of inertia, delayed mineralization (reduced mineral/matrix ratio, increased acid phosphate content), higher tissue-level strains, and reduced whole-bone strength and stiffness, recapitulating features of skeletal aging and establishing a functional role for GORAB in bone integrity in vivo.","method":"Conditional gene knockout (Cre-lox), microCT imaging, FTIR imaging, in vivo strain gauge, finite element analysis, three-point bending tests","journal":"Journal of biomechanics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — well-controlled conditional KO with multiple orthogonal phenotypic readouts; mechanistic pathway not fully resolved but loss-of-function phenotype clearly defined","pmids":["29108851"],"is_preprint":false}],"current_model":"GORAB is a trans-Golgi golgin that forms stable membrane domains by interacting with RAB6 and ARF5 (via its IGRAB domain) and with the COPI-binding protein SCYL1; through these interactions it scaffolds COPI recruitment, enabling retrograde retrieval of Golgi-resident glycosylation enzymes, such that GORAB loss impairs protein glycosylation and causes the progeroid skin-and-bone disorder gerodermia osteodysplastica. Additionally, GORAB has been reported to stabilize p53 by suppressing MDM2-mediated ubiquitination and to regulate neurite outgrowth via the MDM2/p53 axis, though these functions are less well characterized."},"narrative":{"mechanistic_narrative":"GORAB is a trans-Golgi golgin that scaffolds COPI-mediated retrograde transport and is required for normal protein glycosylation, with its loss causing the progeroid skin-and-bone disorder gerodermia osteodysplastica [PMID:18997784, PMID:30631079]. It associates loosely with trans-Golgi membranes—being rapidly displaced by Brefeldin A—through an internal IGRAB domain that binds both the small GTPase RAB6 and the GTP-bound active form of ARF5 [PMID:18997784, PMID:26000619]. At the trans-Golgi, GORAB assembles into stable membrane domains that, via interaction with the COPI-binding protein SCYL1, recruit COPI to enable retrieval of trans-Golgi glycosylation enzymes; loss of GORAB impairs this retrieval and produces deficient glycosylation of secretory cargo [PMID:30631079]. Pathogenic missense mutations map to the IGRAB domain and disrupt this machinery: p.Ala220Pro mislocalizes GORAB to the cytoplasm and abolishes both RAB6 and ARF5 binding, while p.Ser175Phe displaces it to vesicular structures and selectively impairs ARF5 binding [PMID:26000619], and other mutations perturb SCYL1 binding or domain assembly [PMID:30631079]. In vivo, conditional deletion of Gorab in long bones recapitulates skeletal aging, with reduced cortical bone, delayed mineralization, and diminished whole-bone strength, establishing GORAB as required for bone integrity [PMID:29108851]. Separately, GORAB has been reported to act in a nuclear MDM2/p53 axis—stabilizing p53 by suppressing MDM2-mediated ubiquitination [PMID:20849854] and inhibiting neurite outgrowth and axonal regeneration by inducing Mdm2 transcription to lower p53 levels [PMID:23051735]—a role less integrated with its Golgi function.","teleology":[{"year":2008,"claim":"Established GORAB's identity and disease relevance by showing it is a Golgi-localized RAB6-binding golgin whose loss causes gerodermia osteodysplastica, defining the secretory pathway as the disease mechanism.","evidence":"Patient mutation identification with subcellular localization and protein interaction assays","pmids":["18997784"],"confidence":"High","gaps":["Did not define the membrane-targeting domain or the molecular consequence of RAB6 binding","No link yet to a downstream transport step or cargo"]},{"year":2009,"claim":"Confirmed loss-of-function as the pathogenic mechanism by showing a missense mutation produces a null-equivalent phenotype in gerodermia osteodysplastica families.","evidence":"Homozygosity mapping and linkage analysis in Saudi families","pmids":["19681135"],"confidence":"Low","gaps":["Genetic mapping only, no direct functional assay of the missense allele","Does not extend the molecular model"]},{"year":2010,"claim":"Proposed a nuclear function by showing GORAB overexpression stabilizes p53 through suppression of MDM2-specific ubiquitination, coupling it to growth arrest and apoptosis.","evidence":"Ubiquitination assays with MDM2 specificity control, transcriptional reporters, proliferation/apoptosis/tumorigenicity assays","pmids":["20849854"],"confidence":"Medium","gaps":["Relies on overexpression; endogenous relevance unestablished","Mechanism of MDM2 inhibition not resolved","Not reconciled with the Golgi localization established earlier"]},{"year":2012,"claim":"Extended the p53 connection to neuronal biology by showing GORAB represses neurite outgrowth and axonal regeneration via transcriptional induction of Mdm2 and consequent p53 degradation.","evidence":"Overexpression/shRNA in PC12 cells and primary neurons, neurite assays, Mdm2 promoter assay, siRNA epistasis, in vivo regeneration model","pmids":["23051735"],"confidence":"Medium","gaps":["Direction of p53 effect (degradation here vs. stabilization in 2010) not reconciled","Transcriptional activator role not biochemically defined","Mdm2 siRNA rescue only partial"]},{"year":2015,"claim":"Defined the membrane-targeting mechanism by mapping an IGRAB domain that binds RAB6 and active ARF5, and tied two disease mutations to specific binding/localization defects.","evidence":"Yeast two-hybrid, fluorescence microscopy, Brefeldin A displacement, site-directed mutagenesis of pathogenic mutations","pmids":["26000619"],"confidence":"High","gaps":["Did not establish the downstream transport step served by RAB6/ARF5 binding","Functional role of ARF5 vs RAB6 binding distinct contributions unresolved"]},{"year":2017,"claim":"Demonstrated a tissue-level in vivo requirement by showing conditional Gorab deletion in long bones recapitulates skeletal aging with reduced mineralization and bone strength.","evidence":"Cre-lox conditional knockout with microCT, FTIR, strain gauge, finite element analysis, three-point bending","pmids":["29108851"],"confidence":"Medium","gaps":["Molecular pathway connecting Golgi/glycosylation defect to bone phenotype not resolved","Cell-type-specific mechanism in osteoblasts not defined"]},{"year":2019,"claim":"Provided the unifying molecular function: GORAB forms stable trans-Golgi domains that recruit COPI via SCYL1 to enable retrieval of glycosylation enzymes, explaining the glycosylation defect underlying disease.","evidence":"Co-immunoprecipitation, GORAB knockout/knockdown, COPI recruitment and glycosylation assays, pathogenic mutation analysis","pmids":["30631079"],"confidence":"High","gaps":["Specific enzymes whose retrieval depends on GORAB not exhaustively identified","Structural basis of domain assembly unresolved","Relationship between Golgi function and the MDM2/p53 axis not established"]},{"year":null,"claim":"How the trans-Golgi COPI-scaffolding function relates mechanistically to the reported nuclear MDM2/p53 activity, and how either pathway causes the skin and bone pathology, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No experiment links Golgi/glycosylation function to p53 regulation","Causal chain from glycosylation defect to gerodermia osteodysplastica phenotype not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[2]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,2]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[0,1,2]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[2]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2]}],"complexes":[],"partners":["RAB6","ARF5","SCYL1","MDM2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q5T7V8","full_name":"RAB6-interacting golgin","aliases":["N-terminal kinase-like-binding protein 1","NTKL-BP1","NTKL-binding protein 1","hNTKL-BP1","SCY1-like 1-binding protein 1","SCYL1-BP1","SCYL1-binding protein 1"],"length_aa":369,"mass_kda":42.3,"function":"","subcellular_location":"Cytoplasm; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/Q5T7V8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GORAB","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GORAB","total_profiled":1310},"omim":[{"mim_id":"611716","title":"ATPase, H+ TRANSPORTING, LYSOSOMAL, V0 SUBUNIT A2; ATP6V0A2","url":"https://www.omim.org/entry/611716"},{"mim_id":"607983","title":"GOLGIN, RAB6-INTERACTING; GORAB","url":"https://www.omim.org/entry/607983"},{"mim_id":"607982","title":"SCY1-LIKE 1; SCYL1","url":"https://www.omim.org/entry/607982"},{"mim_id":"607680","title":"ZINC FINGER PROTEIN 363; ZNF363","url":"https://www.omim.org/entry/607680"},{"mim_id":"231070","title":"GERODERMA OSTEODYSPLASTICUM; GO","url":"https://www.omim.org/entry/231070"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Golgi apparatus","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GORAB"},"hgnc":{"alias_symbol":["FLJ11752","NTKL-BP1","GO"],"prev_symbol":["SCYL1BP1"]},"alphafold":{"accession":"Q5T7V8","domains":[{"cath_id":"1.20.5","chopping":"132-240","consensus_level":"medium","plddt":93.8079,"start":132,"end":240}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5T7V8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q5T7V8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q5T7V8-F1-predicted_aligned_error_v6.png","plddt_mean":70.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GORAB","jax_strain_url":"https://www.jax.org/strain/search?query=GORAB"},"sequence":{"accession":"Q5T7V8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q5T7V8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q5T7V8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q5T7V8"}},"corpus_meta":[{"pmid":"14681407","id":"PMC_14681407","title":"The Gene Ontology (GO) database and informatics resource.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/14681407","citation_count":3212,"is_preprint":false},{"pmid":"16381878","id":"PMC_16381878","title":"The Gene Ontology (GO) project in 2006.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16381878","citation_count":870,"is_preprint":false},{"pmid":"25336398","id":"PMC_25336398","title":"Small cell lung cancer: where do we go from here?","date":"2014","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25336398","citation_count":506,"is_preprint":false},{"pmid":"18809331","id":"PMC_18809331","title":"HIF-1 regulation: not so easy come, easy go.","date":"2008","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18809331","citation_count":279,"is_preprint":false},{"pmid":"12175476","id":"PMC_12175476","title":"Adipogenesis and aging: does aging make fat go MAD?","date":"2002","source":"Experimental gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/12175476","citation_count":274,"is_preprint":false},{"pmid":"18403029","id":"PMC_18403029","title":"Gephyrin: where do we stand, where do we go?","date":"2008","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/18403029","citation_count":252,"is_preprint":false},{"pmid":"27698656","id":"PMC_27698656","title":"Neutrophil Extracellular Traps Go Viral.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27698656","citation_count":215,"is_preprint":false},{"pmid":"31022923","id":"PMC_31022923","title":"Antibiotic Discovery: Where Have We Come from, Where Do We Go?","date":"2019","source":"Antibiotics (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31022923","citation_count":203,"is_preprint":false},{"pmid":"12142009","id":"PMC_12142009","title":"Yeast go the whole HOG for the hyperosmotic response.","date":"2002","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/12142009","citation_count":199,"is_preprint":false},{"pmid":"26997501","id":"PMC_26997501","title":"Retrograde signaling: Organelles go networking.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26997501","citation_count":167,"is_preprint":false},{"pmid":"15389881","id":"PMC_15389881","title":"To go or not to go: Migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF.","date":"2004","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15389881","citation_count":147,"is_preprint":false},{"pmid":"1702756","id":"PMC_1702756","title":"Where does serum amylase come from and where does it go?","date":"1990","source":"Gastroenterology clinics of North America","url":"https://pubmed.ncbi.nlm.nih.gov/1702756","citation_count":142,"is_preprint":false},{"pmid":"32151052","id":"PMC_32151052","title":"Gene Therapy in Cancer Treatment: Why Go Nano?","date":"2020","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/32151052","citation_count":139,"is_preprint":false},{"pmid":"22632364","id":"PMC_22632364","title":"Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease.","date":"2012","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22632364","citation_count":133,"is_preprint":false},{"pmid":"28033427","id":"PMC_28033427","title":"PIWIs Go Viral: Arbovirus-Derived piRNAs in Vector Mosquitoes.","date":"2016","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/28033427","citation_count":132,"is_preprint":false},{"pmid":"18997784","id":"PMC_18997784","title":"Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18997784","citation_count":129,"is_preprint":false},{"pmid":"15466192","id":"PMC_15466192","title":"Ether a go-go potassium channels as human cervical cancer markers.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15466192","citation_count":127,"is_preprint":false},{"pmid":"30568592","id":"PMC_30568592","title":"FKBP Ligands-Where We Are and Where to Go?","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30568592","citation_count":121,"is_preprint":false},{"pmid":"16918350","id":"PMC_16918350","title":"Round and round we go: cyclic peptides in disease.","date":"2006","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16918350","citation_count":121,"is_preprint":false},{"pmid":"37430086","id":"PMC_37430086","title":"Where should siRNAs go: applicable organs for siRNA drugs.","date":"2023","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37430086","citation_count":117,"is_preprint":false},{"pmid":"19212138","id":"PMC_19212138","title":"Molecular mechanisms of go signaling.","date":"2009","source":"Neuro-Signals","url":"https://pubmed.ncbi.nlm.nih.gov/19212138","citation_count":107,"is_preprint":false},{"pmid":"20801545","id":"PMC_20801545","title":"Macrophage podosomes go 3D.","date":"2011","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20801545","citation_count":107,"is_preprint":false},{"pmid":"20138673","id":"PMC_20138673","title":"Should I stay or should I go? Becoming a granule cell.","date":"2010","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/20138673","citation_count":99,"is_preprint":false},{"pmid":"22301074","id":"PMC_22301074","title":"Manual GO annotation of predictive protein signatures: the InterPro approach to GO curation.","date":"2012","source":"Database : the journal of biological databases and curation","url":"https://pubmed.ncbi.nlm.nih.gov/22301074","citation_count":94,"is_preprint":false},{"pmid":"32582886","id":"PMC_32582886","title":"Round, round we go - strategies for enzymatic cofactor regeneration.","date":"2020","source":"Natural product reports","url":"https://pubmed.ncbi.nlm.nih.gov/32582886","citation_count":94,"is_preprint":false},{"pmid":"10489423","id":"PMC_10489423","title":"Identification of ether à go-go and calcium-activated potassium channels in human melanoma cells.","date":"1999","source":"The Journal of membrane biology","url":"https://pubmed.ncbi.nlm.nih.gov/10489423","citation_count":91,"is_preprint":false},{"pmid":"17022811","id":"PMC_17022811","title":"Ether à go-go potassium channel expression in soft tissue sarcoma patients.","date":"2006","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17022811","citation_count":90,"is_preprint":false},{"pmid":"12408839","id":"PMC_12408839","title":"Nogo on the go.","date":"2002","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/12408839","citation_count":89,"is_preprint":false},{"pmid":"12189484","id":"PMC_12189484","title":"DNA hypermethylation: when tumour suppressor genes go silent.","date":"2002","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12189484","citation_count":86,"is_preprint":false},{"pmid":"16473665","id":"PMC_16473665","title":"Ether à go-go potassium channels and cancer.","date":"2006","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/16473665","citation_count":85,"is_preprint":false},{"pmid":"22083042","id":"PMC_22083042","title":"Targeted therapies: how personal should we go?","date":"2011","source":"Nature reviews. Clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22083042","citation_count":85,"is_preprint":false},{"pmid":"21425403","id":"PMC_21425403","title":"Concise review: mesenchymal tumors: when stem cells go mad.","date":"2011","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/21425403","citation_count":85,"is_preprint":false},{"pmid":"32614384","id":"PMC_32614384","title":"Phospholipid ebb and flow makes mitochondria go.","date":"2020","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32614384","citation_count":84,"is_preprint":false},{"pmid":"26404354","id":"PMC_26404354","title":"Tight Junctions Go Viral!","date":"2015","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/26404354","citation_count":83,"is_preprint":false},{"pmid":"31957016","id":"PMC_31957016","title":"Synucleinopathies: Where we are and where we need to go.","date":"2020","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31957016","citation_count":82,"is_preprint":false},{"pmid":"16699262","id":"PMC_16699262","title":"Acid suppression therapy: where do we go from here?","date":"2006","source":"Digestive diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/16699262","citation_count":79,"is_preprint":false},{"pmid":"23569431","id":"PMC_23569431","title":"MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression.","date":"2013","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23569431","citation_count":75,"is_preprint":false},{"pmid":"18473819","id":"PMC_18473819","title":"Cell death by necrosis, a regulated way to go.","date":"2008","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18473819","citation_count":71,"is_preprint":false},{"pmid":"29333676","id":"PMC_29333676","title":"Ether-à-go-go K+ channels: effective modulators of neuronal excitability.","date":"2018","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29333676","citation_count":68,"is_preprint":false},{"pmid":"12840660","id":"PMC_12840660","title":"Letting lipids go: hormone-sensitive lipase.","date":"2003","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/12840660","citation_count":67,"is_preprint":false},{"pmid":"21131211","id":"PMC_21131211","title":"Where to go with FTO?","date":"2010","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/21131211","citation_count":60,"is_preprint":false},{"pmid":"15364405","id":"PMC_15364405","title":"Expression of ether à go-go potassium channels in human gliomas.","date":"2004","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/15364405","citation_count":60,"is_preprint":false},{"pmid":"27575264","id":"PMC_27575264","title":"Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It.","date":"2016","source":"Archives of pathology & laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27575264","citation_count":56,"is_preprint":false},{"pmid":"35379738","id":"PMC_35379738","title":"To go or not to go? Biological logic gating engineered T cells.","date":"2022","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35379738","citation_count":50,"is_preprint":false},{"pmid":"30362507","id":"PMC_30362507","title":"Melanoma: Where we are and where we go.","date":"2018","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30362507","citation_count":47,"is_preprint":false},{"pmid":"27249773","id":"PMC_27249773","title":"How Far Do We Go With Genetic Evaluation? Gene, Panel, and Tumor Testing.","date":"2016","source":"American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting","url":"https://pubmed.ncbi.nlm.nih.gov/27249773","citation_count":47,"is_preprint":false},{"pmid":"27372352","id":"PMC_27372352","title":"Go in! Go out! Inducible control of nuclear localization.","date":"2016","source":"Current opinion in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/27372352","citation_count":46,"is_preprint":false},{"pmid":"35094062","id":"PMC_35094062","title":"How low can they go? Aerobic respiration by microorganisms under apparent anoxia.","date":"2022","source":"FEMS microbiology reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35094062","citation_count":46,"is_preprint":false},{"pmid":"31984178","id":"PMC_31984178","title":"Gō model revisited.","date":"2019","source":"Biophysics and physicobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31984178","citation_count":45,"is_preprint":false},{"pmid":"21655246","id":"PMC_21655246","title":"Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21655246","citation_count":45,"is_preprint":false},{"pmid":"30631079","id":"PMC_30631079","title":"GORAB scaffolds COPI at the trans-Golgi for efficient enzyme recycling and correct protein glycosylation.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30631079","citation_count":44,"is_preprint":false},{"pmid":"19261185","id":"PMC_19261185","title":"When is it time for reverse transcription to start and go?","date":"2009","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/19261185","citation_count":43,"is_preprint":false},{"pmid":"12445642","id":"PMC_12445642","title":"Characterization of the GO system of Pseudomonas aeruginosa.","date":"2002","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12445642","citation_count":42,"is_preprint":false},{"pmid":"23015375","id":"PMC_23015375","title":"We still have a long way to go to effectively deliver genes!","date":"2012","source":"Journal of applied biomaterials & functional materials","url":"https://pubmed.ncbi.nlm.nih.gov/23015375","citation_count":41,"is_preprint":false},{"pmid":"10455180","id":"PMC_10455180","title":"New ether-à-go-go K(+) channel family members localized in human telencephalon.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10455180","citation_count":40,"is_preprint":false},{"pmid":"38817664","id":"PMC_38817664","title":"Immunotherapy for esophageal cancer: Where are we now and where can we go.","date":"2024","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/38817664","citation_count":39,"is_preprint":false},{"pmid":"12932080","id":"PMC_12932080","title":"Hibernation: when good clocks go cold.","date":"2003","source":"Journal of biological rhythms","url":"https://pubmed.ncbi.nlm.nih.gov/12932080","citation_count":38,"is_preprint":false},{"pmid":"30656387","id":"PMC_30656387","title":"IL-33 in obesity: where do we go from here?","date":"2019","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/30656387","citation_count":38,"is_preprint":false},{"pmid":"23051735","id":"PMC_23051735","title":"SCYL1BP1 modulates neurite outgrowth and regeneration by regulating the Mdm2/p53 pathway.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/23051735","citation_count":37,"is_preprint":false},{"pmid":"18829842","id":"PMC_18829842","title":"G protein-coupled receptors go extracellular: RhoA integrates the integrins.","date":"2008","source":"Molecular interventions","url":"https://pubmed.ncbi.nlm.nih.gov/18829842","citation_count":37,"is_preprint":false},{"pmid":"15283985","id":"PMC_15283985","title":"When biotech proteins go off-patent.","date":"2004","source":"Trends in biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/15283985","citation_count":37,"is_preprint":false},{"pmid":"18840523","id":"PMC_18840523","title":"Unphosphorylated STATs go nuclear.","date":"2008","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/18840523","citation_count":34,"is_preprint":false},{"pmid":"35003116","id":"PMC_35003116","title":"Targeting TREM2 for Parkinson's Disease: Where to Go?","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35003116","citation_count":34,"is_preprint":false},{"pmid":"23239350","id":"PMC_23239350","title":"The elusive compass of clostridial neurotoxins: deciding when and where to go?","date":"2013","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23239350","citation_count":34,"is_preprint":false},{"pmid":"28661898","id":"PMC_28661898","title":"Genomic testing for localized prostate cancer: where do we go from here?","date":"2017","source":"Current opinion in urology","url":"https://pubmed.ncbi.nlm.nih.gov/28661898","citation_count":33,"is_preprint":false},{"pmid":"22110192","id":"PMC_22110192","title":"Novel curcumin analogs, GO-Y030 and GO-Y078, are multi-targeted agents with enhanced abilities for multiple myeloma.","date":"2011","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22110192","citation_count":32,"is_preprint":false},{"pmid":"25910230","id":"PMC_25910230","title":"Existence and control of Go/No-Go decision transition threshold in the striatum.","date":"2015","source":"PLoS computational biology","url":"https://pubmed.ncbi.nlm.nih.gov/25910230","citation_count":32,"is_preprint":false},{"pmid":"26000619","id":"PMC_26000619","title":"GORAB Missense Mutations Disrupt RAB6 and ARF5 Binding and Golgi Targeting.","date":"2015","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26000619","citation_count":30,"is_preprint":false},{"pmid":"12969389","id":"PMC_12969389","title":"Pregnancy in dialysis patients: where do we go from here?","date":"2003","source":"Seminars in dialysis","url":"https://pubmed.ncbi.nlm.nih.gov/12969389","citation_count":30,"is_preprint":false},{"pmid":"29659511","id":"PMC_29659511","title":"Quorum Sensing and Quorum Quenching in Agrobacterium: A \"Go/No Go System\"?","date":"2018","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/29659511","citation_count":29,"is_preprint":false},{"pmid":"33204231","id":"PMC_33204231","title":"Biocatalytic membrane: Go far beyond enzyme immobilization.","date":"2020","source":"Engineering in life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33204231","citation_count":29,"is_preprint":false},{"pmid":"19681135","id":"PMC_19681135","title":"A novel missense mutation in SCYL1BP1 produces geroderma osteodysplastica phenotype indistinguishable from that caused by nullimorphic mutations.","date":"2009","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/19681135","citation_count":28,"is_preprint":false},{"pmid":"18096051","id":"PMC_18096051","title":"Improved functional expression of recombinant human ether-a-go-go (hERG) K+ channels by cultivation at reduced temperature.","date":"2007","source":"BMC biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/18096051","citation_count":28,"is_preprint":false},{"pmid":"1840457","id":"PMC_1840457","title":"Growth cone transduction: Go and GAP-43.","date":"1991","source":"Journal of cell science. Supplement","url":"https://pubmed.ncbi.nlm.nih.gov/1840457","citation_count":27,"is_preprint":false},{"pmid":"35797055","id":"PMC_35797055","title":"Kv Channel Ancillary Subunits: Where Do We Go from Here?","date":"2022","source":"Physiology (Bethesda, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/35797055","citation_count":25,"is_preprint":false},{"pmid":"26728852","id":"PMC_26728852","title":"Lipid droplets go nuclear.","date":"2016","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26728852","citation_count":25,"is_preprint":false},{"pmid":"31039144","id":"PMC_31039144","title":"Gene-edited babies: What went wrong and what could go wrong.","date":"2019","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/31039144","citation_count":24,"is_preprint":false},{"pmid":"10537763","id":"PMC_10537763","title":"Glaucoma genetics: where are we? Where will we go?","date":"1999","source":"Current opinion in ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/10537763","citation_count":24,"is_preprint":false},{"pmid":"33427841","id":"PMC_33427841","title":"Nanozymes go oral: nanocatalytic medicine facilitates dental health.","date":"2021","source":"Journal of materials chemistry. B","url":"https://pubmed.ncbi.nlm.nih.gov/33427841","citation_count":24,"is_preprint":false},{"pmid":"19214999","id":"PMC_19214999","title":"Developmental adaptation: where we go from here.","date":"2009","source":"American journal of human biology : the official journal of the Human Biology Council","url":"https://pubmed.ncbi.nlm.nih.gov/19214999","citation_count":23,"is_preprint":false},{"pmid":"23124700","id":"PMC_23124700","title":"Sexing mammalian sperm - Where do we go from here?","date":"2012","source":"The Journal of reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/23124700","citation_count":23,"is_preprint":false},{"pmid":"17381325","id":"PMC_17381325","title":"X-chromosome kiss and tell: how the Xs go their separate ways.","date":"2006","source":"Cold Spring Harbor symposia on quantitative biology","url":"https://pubmed.ncbi.nlm.nih.gov/17381325","citation_count":22,"is_preprint":false},{"pmid":"29108851","id":"PMC_29108851","title":"Examining tissue composition, whole-bone morphology and mechanical behavior of GorabPrx1 mice tibiae: A mouse model of premature aging.","date":"2017","source":"Journal of biomechanics","url":"https://pubmed.ncbi.nlm.nih.gov/29108851","citation_count":22,"is_preprint":false},{"pmid":"27063953","id":"PMC_27063953","title":"Oct-1, to go or not to go? That is the PolII question.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/27063953","citation_count":21,"is_preprint":false},{"pmid":"37973823","id":"PMC_37973823","title":"Durotaxis and negative durotaxis: where should cells go?","date":"2023","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/37973823","citation_count":21,"is_preprint":false},{"pmid":"26766168","id":"PMC_26766168","title":"Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?","date":"2016","source":"Blood purification","url":"https://pubmed.ncbi.nlm.nih.gov/26766168","citation_count":21,"is_preprint":false},{"pmid":"36226233","id":"PMC_36226233","title":"Gene Therapy and Hemophilia: Where Do We Go from Here?","date":"2022","source":"Journal of blood medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36226233","citation_count":20,"is_preprint":false},{"pmid":"32272661","id":"PMC_32272661","title":"Papillomaviruses Go Retro.","date":"2020","source":"Pathogens (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32272661","citation_count":19,"is_preprint":false},{"pmid":"26787641","id":"PMC_26787641","title":"Touch, act and go: landing and operating on nucleosomes.","date":"2016","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/26787641","citation_count":19,"is_preprint":false},{"pmid":"38426088","id":"PMC_38426088","title":"Purinergic enzymes on extracellular vesicles: immune modulation on the go.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38426088","citation_count":19,"is_preprint":false},{"pmid":"27687257","id":"PMC_27687257","title":"Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?","date":"2016","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27687257","citation_count":19,"is_preprint":false},{"pmid":"32111739","id":"PMC_32111739","title":"Viruses go modular.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32111739","citation_count":18,"is_preprint":false},{"pmid":"25525868","id":"PMC_25525868","title":"Microexons go big.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25525868","citation_count":18,"is_preprint":false},{"pmid":"24958495","id":"PMC_24958495","title":"Adenosine pathway and cancer: where do we go from here?","date":"2014","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/24958495","citation_count":18,"is_preprint":false},{"pmid":"20425505","id":"PMC_20425505","title":"Occupational rhinitis and asthma: where do we stand, where do we go?","date":"2010","source":"Current allergy and asthma reports","url":"https://pubmed.ncbi.nlm.nih.gov/20425505","citation_count":18,"is_preprint":false},{"pmid":"22456188","id":"PMC_22456188","title":"Should I stay or should I go? Ephs and ephrins in neuronal migration.","date":"2012","source":"Neuro-Signals","url":"https://pubmed.ncbi.nlm.nih.gov/22456188","citation_count":18,"is_preprint":false},{"pmid":"20071423","id":"PMC_20071423","title":"Interactions at human ether-à-go-go-related gene channels.","date":"2010","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/20071423","citation_count":17,"is_preprint":false},{"pmid":"14668215","id":"PMC_14668215","title":"Expression and role of the ether-à-go-go-related (MERG1A) potassium-channel protein during preimplantation mouse development.","date":"2003","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/14668215","citation_count":17,"is_preprint":false},{"pmid":"23578748","id":"PMC_23578748","title":"PTEN plasticity: how the taming of a lethal gene can go too far.","date":"2013","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23578748","citation_count":17,"is_preprint":false},{"pmid":"20849854","id":"PMC_20849854","title":"Overexpression of SCYL1-BP1 stabilizes functional p53 by suppressing MDM2-mediated ubiquitination.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/20849854","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":37189,"output_tokens":2080,"usd":0.071384,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9112,"output_tokens":2809,"usd":0.057892,"stage2_stop_reason":"end_turn"},"total_usd":0.129276,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"GORAB (SCYL1BP1) localizes to the Golgi apparatus and interacts with the small GTPase RAB6, identifying it as a golgin. Loss-of-function mutations in SCYL1BP1 cause gerodermia osteodysplastica, a disorder affecting skin and bone, establishing the Golgi/secretory pathway as the disease mechanism.\",\n      \"method\": \"Mutation identification in patients, subcellular localization experiments, protein-protein interaction assays\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Golgi localization and RAB6 interaction established by direct experiments in a landmark disease-gene paper, replicated by subsequent studies\",\n      \"pmids\": [\"18997784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GORAB localizes preferentially to trans-Golgi markers and is rapidly displaced upon Brefeldin A treatment, indicating a loose membrane association. An internal Golgi-targeting RAB6 and ARF5 binding (IGRAB) domain mediates binding to both RAB6 and ARF5 (in its active GTP-bound form). Two pathogenic missense mutations (p.Ala220Pro and p.Ser175Phe) fall within the IGRAB domain: p.Ala220Pro causes cytoplasmic mislocalization and abolishes both RAB6 and ARF5 binding, while p.Ser175Phe displaces GORAB to vesicular structures and selectively impairs ARF5 binding.\",\n      \"method\": \"Yeast two-hybrid screening, subcellular localization by fluorescence microscopy, Brefeldin A treatment, site-directed mutagenesis of disease-associated missense mutations\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Y2H, microscopy, mutagenesis, BFA displacement), reciprocal binding assays, mechanistic mapping of disease mutations to a defined domain\",\n      \"pmids\": [\"26000619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GORAB acts as a COPI scaffolding factor at the trans-Golgi. It forms stable domains at the trans-Golgi that, via interactions with the COPI-binding protein SCYL1, promote COPI recruitment to these domains. Loss of GORAB impairs COPI-mediated retrieval of trans-Golgi enzymes, resulting in deficient glycosylation of secretory cargo proteins. Pathogenic GORAB mutations perturb either SCYL1 binding or GORAB assembly into domains.\",\n      \"method\": \"Co-immunoprecipitation, GORAB knockout/knockdown, COPI recruitment assays, glycosylation assays of secretory cargo, analysis of pathogenic missense mutations\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods in a single rigorous study (Co-IP, KO functional assays, glycosylation readout, mutant analysis), mechanistically places GORAB in the COPI pathway\",\n      \"pmids\": [\"30631079\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SCYL1BP1 (GORAB) inhibits nerve growth factor-mediated neurite outgrowth in PC12 cells and impairs morphogenesis of primary cortical neurons by reducing p53 protein levels in a manner dependent on its transcriptional activator domain. SCYL1BP1 directly induces Mdm2 transcription, leading to Mdm2-mediated degradation of p53; siRNA knockdown of Mdm2 partially rescues the neurite outgrowth defects. In vivo, SCYL1BP1 suppresses axonal regeneration, while shRNA-mediated knockdown enhances it.\",\n      \"method\": \"Overexpression and shRNA knockdown in PC12 cells and primary neurons, neurite outgrowth assay, p53 protein measurement, Mdm2 promoter transcription assay, siRNA epistasis, in vivo axonal regeneration model\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cellular assays and in vivo experiments in a single lab, with epistasis through Mdm2 siRNA rescue\",\n      \"pmids\": [\"23051735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Overexpression of SCYL1BP1 (GORAB) stabilizes p53 protein by suppressing MDM2-mediated ubiquitination of p53. This effect is specific to MDM2, as SCYL1BP1 does not alter p53 ubiquitination by HPV E6. Elevated SCYL1BP1 leads to increased p21 and GADD45 transcription, reduced proliferation, increased apoptosis, and inhibition of tumorigenicity.\",\n      \"method\": \"Ubiquitination assay, p53 protein level measurement, transcriptional reporter assays, cell proliferation and apoptosis assays, tumorigenicity assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ubiquitination assay with MDM2 specificity control (HPV E6 negative result), multiple functional readouts, single lab\",\n      \"pmids\": [\"20849854\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Mutations in SCYL1BP1 (GORAB) identified in Saudi families with gerodermia osteodysplastica include a missense mutation that produces a phenotype indistinguishable from null mutations, supporting that loss of GORAB golgin function is the pathogenic mechanism.\",\n      \"method\": \"Homozygosity mapping, linkage analysis, mutation identification\",\n      \"journal\": \"American journal of medical genetics. Part A\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — genetic mapping and mutation identification without direct mechanistic assay; supports but does not extend the functional model\",\n      \"pmids\": [\"19681135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Conditional deletion of Gorab in long bones (GorabPrx1 mice) results in decreased cortical bone area, thickness, and moments of inertia, delayed mineralization (reduced mineral/matrix ratio, increased acid phosphate content), higher tissue-level strains, and reduced whole-bone strength and stiffness, recapitulating features of skeletal aging and establishing a functional role for GORAB in bone integrity in vivo.\",\n      \"method\": \"Conditional gene knockout (Cre-lox), microCT imaging, FTIR imaging, in vivo strain gauge, finite element analysis, three-point bending tests\",\n      \"journal\": \"Journal of biomechanics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — well-controlled conditional KO with multiple orthogonal phenotypic readouts; mechanistic pathway not fully resolved but loss-of-function phenotype clearly defined\",\n      \"pmids\": [\"29108851\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GORAB is a trans-Golgi golgin that forms stable membrane domains by interacting with RAB6 and ARF5 (via its IGRAB domain) and with the COPI-binding protein SCYL1; through these interactions it scaffolds COPI recruitment, enabling retrograde retrieval of Golgi-resident glycosylation enzymes, such that GORAB loss impairs protein glycosylation and causes the progeroid skin-and-bone disorder gerodermia osteodysplastica. Additionally, GORAB has been reported to stabilize p53 by suppressing MDM2-mediated ubiquitination and to regulate neurite outgrowth via the MDM2/p53 axis, though these functions are less well characterized.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GORAB is a trans-Golgi golgin that scaffolds COPI-mediated retrograde transport and is required for normal protein glycosylation, with its loss causing the progeroid skin-and-bone disorder gerodermia osteodysplastica [#0, #2]. It associates loosely with trans-Golgi membranes—being rapidly displaced by Brefeldin A—through an internal IGRAB domain that binds both the small GTPase RAB6 and the GTP-bound active form of ARF5 [#0, #1]. At the trans-Golgi, GORAB assembles into stable membrane domains that, via interaction with the COPI-binding protein SCYL1, recruit COPI to enable retrieval of trans-Golgi glycosylation enzymes; loss of GORAB impairs this retrieval and produces deficient glycosylation of secretory cargo [#2]. Pathogenic missense mutations map to the IGRAB domain and disrupt this machinery: p.Ala220Pro mislocalizes GORAB to the cytoplasm and abolishes both RAB6 and ARF5 binding, while p.Ser175Phe displaces it to vesicular structures and selectively impairs ARF5 binding [#1], and other mutations perturb SCYL1 binding or domain assembly [#2]. In vivo, conditional deletion of Gorab in long bones recapitulates skeletal aging, with reduced cortical bone, delayed mineralization, and diminished whole-bone strength, establishing GORAB as required for bone integrity [#6]. Separately, GORAB has been reported to act in a nuclear MDM2/p53 axis—stabilizing p53 by suppressing MDM2-mediated ubiquitination [#4] and inhibiting neurite outgrowth and axonal regeneration by inducing Mdm2 transcription to lower p53 levels [#3]—a role less integrated with its Golgi function.\",\n  \"teleology\": [\n    {\n      \"year\": 2008,\n      \"claim\": \"Established GORAB's identity and disease relevance by showing it is a Golgi-localized RAB6-binding golgin whose loss causes gerodermia osteodysplastica, defining the secretory pathway as the disease mechanism.\",\n      \"evidence\": \"Patient mutation identification with subcellular localization and protein interaction assays\",\n      \"pmids\": [\"18997784\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the membrane-targeting domain or the molecular consequence of RAB6 binding\", \"No link yet to a downstream transport step or cargo\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Confirmed loss-of-function as the pathogenic mechanism by showing a missense mutation produces a null-equivalent phenotype in gerodermia osteodysplastica families.\",\n      \"evidence\": \"Homozygosity mapping and linkage analysis in Saudi families\",\n      \"pmids\": [\"19681135\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Genetic mapping only, no direct functional assay of the missense allele\", \"Does not extend the molecular model\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Proposed a nuclear function by showing GORAB overexpression stabilizes p53 through suppression of MDM2-specific ubiquitination, coupling it to growth arrest and apoptosis.\",\n      \"evidence\": \"Ubiquitination assays with MDM2 specificity control, transcriptional reporters, proliferation/apoptosis/tumorigenicity assays\",\n      \"pmids\": [\"20849854\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relies on overexpression; endogenous relevance unestablished\", \"Mechanism of MDM2 inhibition not resolved\", \"Not reconciled with the Golgi localization established earlier\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended the p53 connection to neuronal biology by showing GORAB represses neurite outgrowth and axonal regeneration via transcriptional induction of Mdm2 and consequent p53 degradation.\",\n      \"evidence\": \"Overexpression/shRNA in PC12 cells and primary neurons, neurite assays, Mdm2 promoter assay, siRNA epistasis, in vivo regeneration model\",\n      \"pmids\": [\"23051735\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direction of p53 effect (degradation here vs. stabilization in 2010) not reconciled\", \"Transcriptional activator role not biochemically defined\", \"Mdm2 siRNA rescue only partial\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the membrane-targeting mechanism by mapping an IGRAB domain that binds RAB6 and active ARF5, and tied two disease mutations to specific binding/localization defects.\",\n      \"evidence\": \"Yeast two-hybrid, fluorescence microscopy, Brefeldin A displacement, site-directed mutagenesis of pathogenic mutations\",\n      \"pmids\": [\"26000619\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish the downstream transport step served by RAB6/ARF5 binding\", \"Functional role of ARF5 vs RAB6 binding distinct contributions unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated a tissue-level in vivo requirement by showing conditional Gorab deletion in long bones recapitulates skeletal aging with reduced mineralization and bone strength.\",\n      \"evidence\": \"Cre-lox conditional knockout with microCT, FTIR, strain gauge, finite element analysis, three-point bending\",\n      \"pmids\": [\"29108851\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular pathway connecting Golgi/glycosylation defect to bone phenotype not resolved\", \"Cell-type-specific mechanism in osteoblasts not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Provided the unifying molecular function: GORAB forms stable trans-Golgi domains that recruit COPI via SCYL1 to enable retrieval of glycosylation enzymes, explaining the glycosylation defect underlying disease.\",\n      \"evidence\": \"Co-immunoprecipitation, GORAB knockout/knockdown, COPI recruitment and glycosylation assays, pathogenic mutation analysis\",\n      \"pmids\": [\"30631079\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific enzymes whose retrieval depends on GORAB not exhaustively identified\", \"Structural basis of domain assembly unresolved\", \"Relationship between Golgi function and the MDM2/p53 axis not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the trans-Golgi COPI-scaffolding function relates mechanistically to the reported nuclear MDM2/p53 activity, and how either pathway causes the skin and bone pathology, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experiment links Golgi/glycosylation function to p53 regulation\", \"Causal chain from glycosylation defect to gerodermia osteodysplastica phenotype not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 2]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RAB6\", \"ARF5\", \"SCYL1\", \"MDM2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":6,"faith_total":6,"faith_pct":100.0}}